^
Association details:
| Biomarker: | EGFR S768I |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | mefatinib (MET306) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Trial for Mefatinib (MET-306) in the treatment of EGFR rare mutations (g719x, l861q, s768i) in Patients with advanced non-small cell lung cancer
Excerpt:
...Only carry EGFR non-classical mutations (G719X, L861Q, S768I, mutations can be combined with each other) 6. ...
Trial ID:
Source:
Title:
A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations
Published date:
06/15/2023
Excerpt:
...we report the results of the phase II open-label, single-arm, multicenter study investigating the efficacy and safety of Mefatinib as first-line therapy for patients with NSCLC harboring uncommon EGFR mutations (ChiCTR2000029058)….The respective ORR and median progression-free survival (PFS) was 94.1% and 20.6 months for patients with G719X (n = 17), 75.0% and 18.7 months for patients with L861Q (n = 4), and 71.4% and 20.6 months for patients with S768I (n = 7)...our study provides preliminary clinical evidence that first-line Mefatinib therapy was effective, provides durable PFS, and has a manageable toxicity profile in patients with stage IIIB–IV NSCLC harboring EGFR G719X, S768I, and/or L861Q mutations.
DOI:
10.1002/cac2.12456
